ArticleInternational journal of hematology2016

Classical Hodgkin lymphoma primary refractory to brentuximab vedotin, with transformation to CD30-positive diffuse large B-cell lymphoma.

Shinichi Makita et al.PubMed ↗Publisher ↗

No numbers read from the abstract.